Naslov
Serotonin and side effects of antipsychotics

Autori
Švob Štrac, Dubravka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni

Skup
5th Meeting of Mediterranean Neuroscience Society

Mjesto i datum
Santa Margherita di Pula, Italija, 12.06.2015. - 15.06.2015

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
serotonin ; antipsychotics ; side-effects

Sažetak
Schizophrenia is a serious chronic psychiatric disorder, diverse in its clinical presentation, course of the disease and response to therapy. Lifelong treatment of schizophrenia is necessary to maintain social functioning and prevent chronic irreversible personality damage as well as relapse of symptoms. The neurobiological basis of schizophrenia is still insufficiently known, resulting in only partially successful treatment. This complex disease is treated with antipsychotic drugs, which are usually divided into first-generation antipsychotics (FGA), especially effective in the treatment of positive symptoms, and second-generation antipsychotic (SGA), which can reduce both the positive and negative symptoms of schizophrenia. Some patients do not respond satisfactorily to antipsychotics, while others develop side-effects that substantially compromise the treatment, leading to discontinuation of therapy and frequent relapse of the disease. Acute or chronic extrapyramidal symptoms (EPS) appear frequently in patients treated with FGA, while side effects such as metabolic syndrome (MetSy) are often associated with the treatment with SGA. Various side effects of antipsychotics could be related to their different molecular targets, namely dopaminergic D2 (for FGA and SGA), or serotonergic 5- HT2A (for SGA) receptors. FGA and SGA are both antagonists of D2 receptors, but in contrast to the tight blockade of D2 receptors by FGA, the binding of SGA to D2 receptors does not last long enough to induce EPS. Although the EPS are mostly related to the dopaminergic system, pharmacological studies also suggest the connection between antipsychotics, EPS and serotonergic system, probably via serotonergic receptors or by the effects of serotonin on dopamine release in the dopaminergic pathways. In order to improve schizophrenia therapy, recent studies are focusing on the genetic background of individual differences in the response to antipsychotic treatment as well as in the development of EPS.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA